UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

The Lancet (British edition), 2016-05, Vol.387 (10031), p.1909-1920

2016

Volltextzugriff (PDF)

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

Journal for immunotherapy of cancer, 2016-10, Vol.4 (1), p.64, Article 64

2016

Volltextzugriff (PDF)

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

European journal of cancer (1990), 2019-02, Vol.108, p.69-77

2019

Volltextzugriff (PDF)

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Canadian Urological Association journal, 2021-04, Vol.15 (4), p.84-97

2021

Volltextzugriff (PDF)

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium

European urology oncology, 2020-08, Vol.3 (4), p.530-539

2020

Volltextzugriff (PDF)

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

Canadian Urological Association journal, 2023-05, Vol.17 (5), p.E154-63

2023

Volltextzugriff (PDF)

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma

Current oncology (Toronto), 2021-06, Vol.28 (3), p.1744-1750

2021

Volltextzugriff (PDF)

Kidney cancer survivorship survey of urologists and survivors: The gap in perceptions of care, but agreement on needs

Canadian Urological Association journal, 2014-05, Vol.8 (5-6), p.190-194

2014

Volltextzugriff (PDF)

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Canadian Urological Association journal, 2019-10, Vol.13 (10), p.318-327

2019

Volltextzugriff (PDF)

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.927-933

2011

Volltextzugriff (PDF)

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Advances in radiation oncology, 2022-07, Vol.7 (4), p.100899-100899, Article 100899

2022

Volltextzugriff (PDF)

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Canadian Urological Association journal, 2013-02, Vol.7 (1-2), p.E44-E56

2013

Volltextzugriff (PDF)

Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma

Clinical lung cancer, 2013-05, Vol.14 (3), p.238-244

2013

Volltextzugriff (PDF)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

European journal of cancer (1990), 2021-01, Vol.142, p.132-140

2021

Volltextzugriff (PDF)

Fostering partnerships in survivorship care: report of the 2011 Canadian genitourinary cancers survivorship conference

Journal of cancer survivorship, 2012-09, Vol.6 (3), p.296-304

2012

Volltextzugriff (PDF)

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4555-4555

2015

Volltextzugriff (PDF)

Surgical Management of Genitourinary Cancer Liver Metastases

Surgical oncology clinics of North America, 2021-01, Vol.30 (1), p.89-102

2021

Volltextzugriff (PDF)

A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS7-TPS7

2020

Volltextzugriff (PDF)

2023 European Society for Medical Oncology

Canadian Urological Association journal, 2024-01, Vol.18 (1), p.E46

2024

Volltextzugriff (PDF)

Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16501-e16501

2019

Volltextzugriff (PDF)

Should Bisphosphonates Be Used Routinely in Patients With Prostate Cancer Metastatic to Bone?

JNCI : Journal of the National Cancer Institute, 2002-10, Vol.94 (19), p.1422-1432

2002

Volltextzugriff (PDF)

UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.117-117

2021

Volltextzugriff (PDF)

The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e17005-e17005

2018

Volltextzugriff (PDF)

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

JAMA network open, 2021-01, Vol.4 (1), p.e2021869-e2021869

2021

Volltextzugriff (PDF)

2023 European Society for Medical Oncology (ESMO) Congress Meeting highlights

Canadian Urological Association journal, 2024-01, Vol.18 (1), p.E46-52

2024

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(92)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Oncology
(27)
Humans
(23)
Urology & Nephrology
(23)
Male
(16)
Middle Aged
(15)
Aged
(14)
Cancer
(14)
Female
(13)
Care And Treatment
(12)
Metastasis
(12)
Prostate Cancer
(11)
Patients
(9)
Medicine
(8)
Medicine & Public Health
(7)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Consensus Statement
(6)
Renal Cell Carcinoma
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma

Kidney cancer survivorship survey of urologists and survivors: The gap in perceptions of care, but agreement on needs

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

Fostering partnerships in survivorship care: report of the 2011 Canadian genitourinary cancers survivorship conference

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC)

Surgical Management of Genitourinary Cancer Liver Metastases

A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA)

2023 European Society for Medical Oncology

Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer

Should Bisphosphonates Be Used Routinely in Patients With Prostate Cancer Metastatic to Bone?

UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer

The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

2023 European Society for Medical Oncology (ESMO) Congress Meeting highlights

Suchergebnisse filtern